Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-Positive Non-Small Cell Lung Cancer (NSCLC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02737501
What this trial is testing

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

Who this might be right for
Non-small Cell Lung CancerLung CancerAdvanced Malignancies+1 more
Ariad Pharmaceuticals 275
Not applicableNot Yet RecruitingNCT07674524
What this trial is testing

Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)HyperlipidemiaALK Gene Mutation+1 more
Sun Yat-sen University 160
Not applicableStudy completedNCT01597258
What this trial is testing

Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)

Who this might be right for
Non-small Cell Lung Cancer
Pfizer 2,029
Testing effectiveness (Phase 2)Ended earlyNCT02521051
What this trial is testing

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Massachusetts General Hospital 11
Not applicableEnrolling By InvitationNCT06846736
What this trial is testing

ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study

Who this might be right for
Alk-positive Non-Small Cell Lung CancerALK-inhibitor Treated
Sheba Medical Center 200
Early research (Phase 1)Study completedNCT02299505
What this trial is testing

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 306
Large-scale testing (Phase 3)Study completedNCT01828099
What this trial is testing

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 376
Large-scale testing (Phase 3)Study completedNCT03194893
What this trial is testing

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Who this might be right for
Neoplasms
Hoffmann-La Roche 50
Large-scale testing (Phase 3)Looking for participantsNCT06765109
What this trial is testing

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Who this might be right for
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive
Nuvalent Inc. 450
Testing effectiveness (Phase 2)Active Not RecruitingNCT05200481
What this trial is testing

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Who this might be right for
Non Small Cell Lung CancerALK Gene Mutation
Intergroupe Francophone de Cancerologie Thoracique 110
Testing effectiveness (Phase 2)UnknownNCT04641754
What this trial is testing

A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 176
Testing effectiveness (Phase 2)UnknownNCT03215693
What this trial is testing

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Who this might be right for
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 152
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 156
Large-scale testing (Phase 3)UnknownNCT04632758
What this trial is testing

Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 292
Early research (Phase 1)Study completedNCT02292550
What this trial is testing

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 27
Large-scale testing (Phase 3)Study completedNCT02838420
What this trial is testing

Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Hoffmann-La Roche 187
Not applicableLooking for participantsNCT06862869
What this trial is testing

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 800
Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Testing effectiveness (Phase 2)UnknownNCT05869162
What this trial is testing

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Who this might be right for
Non-small-cell Lung Carcinoma
Shouyao Holdings (Beijing) Co. LTD 153
Testing effectiveness (Phase 2)Looking for participantsNCT06092086
What this trial is testing

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Who this might be right for
ALK Positive Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 126
Next Page